Iannone Robert sold $19.2M of JAZZ

Jazz Pharmaceuticals extended and repriced its $1.9B loan, pushing the maturity date to 2033 and reducing the interest rate by 50 basis points. The company borrowed an additional $273.3M to refinance existing debt, with the new tranche amortizing over 25 years.

Jazz Pharmaceuticals presented data at SLEEP 2026 showing Xywav's dosing flexibility for narcolepsy and idiopathic hypersomnia, with stable regimens achievable in ~42 days. Real-world data indicates 91% use twice-nightly regimens, but clinicians often customize doses. Studies also show cardiovascular benefits of low-sodium oxybate. According to Jazz, Xywav's individualized dosing can improve patient outcomes.

Jazz Pharmaceuticals (JAZZ) targets $5B opportunity for zanidatamab, with oncology revenue exceeding $1B. The company expects strong adoption of the triplet regimen and sees limited near-term competition. Jazz also reported 40% growth for Zepzelca and strong early adoption for Modeyso. The company generated $824M cash in H1 and raised $1B through a convertible offering, with plans for further investments and acquisitions.

Jazz Pharmaceuticals (JAZZ) raised its revenue estimate for Ziihera to $3B-$5B, citing potential expansion in multiple cancer types. The company expects Ziihera to become a first-line standard of care for HER2-positive gastroesophageal adenocarcinoma. Jazz also announced pipeline expansions in epilepsy and sleep-wake disorders, including new clinical trials and formulations.

Jazz Pharmaceuticals (JAZZ) acquired Actio Biosciences for $820M, with potential $500M in milestone payments, to gain control of ABS-1230, a treatment for rare childhood epilepsy. Jazz reported Q2 revenue of $1.2B, up 16% YoY, and raised 2026 guidance to $4.6B-$4.75B. The company also acquired Chimerix for $944M in 2025. ABS-1230 is in Phase 1b/2a trials, with early results showing seizure reductions. Jazz trades at ~9.5x forward earnings, offering growth potential but with clinical risks.

Jazz Pharmaceuticals (JAZZ) acquired Actio Biosciences for $820M, adding epilepsy drug ABS-1230 to its pipeline. Jazz reported record Q2 revenue of $1.2B and raised 2026 guidance to $4.6B-$4.75B. The deal adds to existing debt, and ABS-1230 is in early clinical stages. Jazz's shares trade at a forward P/E of 11.03.